To access this page on Cerebrolysin® please confirm
that you are a healthcare professional.
NO, I AM NOT A HEALTHCARE PROFESSIONAL

News

Follow-up on 23rd AMN Congress

May 28-30, 2026 — Istanbul, Türkiye
read more
26.06.2026

Post-stroke cognitive impairment

An underestimated burden after stroke
Read more
06.05.2026

New 12-Month Follow-up Study

Cerebrolysin® as an Adjunct Therapy to Mechanical Thrombectomy
Read more
22.04.2026

23rd AMN Congress

28-30 May, 2026 in Istanbul, Turkey
Read more
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.